Keytruda Mesothelioma Trial, Pembrolizumab Does Not Outperform Chemotherapy In Mesothelioma Cancer Therapy Advisor

A new clinical trial combining keytruda with tumor treating fields for non small cell lung cancer could lead to more effective mesothelioma treatments.

Cartoon coloring pages for kids. The keynote 028 clinical trial conducted in 13 different sites across six different countries was the first to show success using keytruda to treat malignant pleural mesothelioma patients who were previously treated with chemotherapy or were considered ineligible for treatment. Approval for keytruda expands hope for mesothelioma patients. The mesothelioma clinical trial will involve pembrolizumab also known by the brand name keytruda and its synergy with oncos 102 a lesser known genetically modified adenovirus.

Researchers reported that 14 of 25 participants 56 experienced. Malignant mesothelioma tumors often express high levels of pd l1 which is typically a requirement for keytruda eligibility. Results from a phase 3 clinical trial involving keytruda.

Keytruda has been especially effective for some but only for a small percentage of mesothelioma patients. The fdas approval occurred tuesday june 16 2020. Participants in the control group who received standard chemotherapy were able to switch to keytruda if their mesothelioma progressed or spread during the trial.

Participants received either keytruda or a standard chemotherapy drug gemcitabine or vinorelbine. The trial consisted of 144 randomized mesothelioma patients. A number of mesothelioma patients already are being treated with pembrolizumab in clinical trials or under special access programs through manufacturer merck co the pharmaceutical giant.

Standard of care treatment for malignant mesothelioma could change significantly depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. Using the immune system to fight mesothelioma. Keytruda is the brand name of the drug pembrolizumab which has been featured in a number of mesothelioma clinical trials.

In the study researchers compared keytruda to standard mesothelioma chemotherapy cisplatin and pemetrexed. Toll free 855 404 4592 mesothelioma. The european society of medical oncology esmo conference last month included results from the phase 3 promise pleural mesothelioma clinical trial.

Keytruda is paving the way to a new strategy for better treatment of mesothelioma. This date is a little more than one year after the fda granted approval for a tumor treating fields device for pleural mesothelioma. In june of 2019 the fda announced a new indication for keytruda.

There are now more than ninety on going clinical trials using keytruda to treat various types of cancers. Interestingly keytruda performed better in mesothelioma patients with a low total proportional score for pd l1 expression in the promise meso trial although the numbers were small.